Taft Chicago partners Stephen Auten and Roshan Shrestha, Ph.D., will present “Strategic Insights: Maintaining the 180-Day Marketing Exclusivity and a Later Filer’s Path to Trigger Forfeiture” on March 5 at the 13th Annual Pharma IPR Conference in Mumbai, India. Speakers will discuss their findings from the Diclofenac case on strategic litigation management in the context of 180-day exclusivity and its forfeiture.

The conference will offer insights from key industry stakeholders on effective IP management to protect innovations in the pharmaceutical industry. For more information, click here.

Auten is chair of Taft’s Pharmaceutical and Life Sciences Litigation group. He is widely known in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators, and others on his LinkedIn blog, “Hatch Waxman ANDA Litigation Forum,” which has more than 14,000 members worldwide. Auten represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities.

Shrestha focuses his practice on all aspects of intellectual property law, including patent litigation, prosecution, and opinion work in the chemical, pharmaceutical, and electronic material arts. He has a broad scope of pharmaceutical and life sciences capabilities, including Hatch-Waxman litigation and inner parts review proceedings at the USPTO. Shrestha has been recognized by Super Lawyers and Leading Lawyers Network and was named to Law Bulletin’s “40 Illinois Attorneys Under 40 to Watch.”